Loading video...
Video Failed to Load
Open, community-funded science is already producing real outcomes. Eli Lilly just bought Crossbridge Bio for $300M. The company grew out of one of the ecosystem's earliest community-funded research grants. Years in the making. Across the ecosystem so far: $2B+ in research IP traded, $50M+ into real science.
16,834 views • 2 months ago •via X (Twitter)
7 Comments

@erhanunal Sonuç yok reis asagi şort

Bio could become the low-cost operating system for agentic science. But the transition from a highly promising project to a high-conviction gem requires passing three tests: PeptAI must publish quantitative, replicable experimental results. BIOS must demonstrate prospectively that its ranking improves wet-lab hit rates. Bio must clarify how revenue, data, IP, and equity generate measurable value for BIO and veBIO.

하 또 사기치네

💡 $BIO at a glance Emma AI has more details @BlockIndexAI 🔥 Sign up free at

Congrats on this milestone for decentralized science Crossbridge Bio's $300M acquisition by Eli Lilly shows community-funded research via VitaDAO can deliver real commercial outcomes after years of development.

Yahu yeter artık.neden alsınlar. Aldırıp durma. Seni bile kandırıyorlar. Bu kadar kişinin vebali çok ağır Erhan kardeşim sana. Uyuyamazsin

let’s revive desci again team!

